Aldactone and Erbitux drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Aldactone (spironolactone) and Erbitux (cetuximab). Common drug interactions include lethargy among females and mucosal inflammation among males.

The phase IV clinical study analyzes what interactions people have when they take Aldactone and Erbitux. It is created by eHealthMe based on reports of 70 people who take the same drugs from the FDA, and is updated regularly.

What is Aldactone?

Aldactone has active ingredients of spironolactone. It is often used in acne. eHealthMe is studying from 46,063 Aldactone users. Check the latest studies of Aldactone.

What is Erbitux?

Erbitux has active ingredients of cetuximab. It is often used in cancer. eHealthMe is studying from 19,276 Erbitux users. Check the latest studies of Erbitux.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 31, 2026

70 people who take Aldactone and Erbitux together, and have interactions are studied.

Aldactone and Erbitux drug interactions.

What are the common drug interactions of Aldactone and Erbitux, by gender? *:

female:

Lethargy (tiredness)
Malaise (a feeling of general discomfort or uneasiness)
Melaena (the passage of black, tarry stools)
Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)
Platelet count decreased
Anorexia (eating disorder characterized by immoderate food restriction and irrational fear of gaining weight)
Blood alkaline phosphatase increased
Cyanosis (lack of oxygen in body leads to blue appearance of skin ,mucous membrane nails)
Death
Dysphagia (a condition in which swallowing is difficult or painful)

male:

Mucosal inflammation (infection of mucous membrane)
Pneumonia aspiration (bronchopneumonia that develops due to the entrance of foreign materials into the bronchial tree)
Pulmonary oedema (fluid accumulation in the lungs)
Dermatitis acneiform (dermatoses including acne vulgaris, rosacea, folliculitis, and perioral dermatitis)
Disseminated intravascular coagulation (systemic activation of blood coagulation)
Dysphagia (a condition in which swallowing is difficult or painful)
General physical health deterioration (weak health status)
Pain
Stevens-johnson syndrome (an immune-complex-mediated hypersensitivity disorder. it ranges from mild skin and mucous membrane lesions to a severe)
Acute respiratory distress syndrome

What are the common drug interactions of Aldactone and Erbitux, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Hyperbilirubinaemia (excess of bilirubin in the blood)
Anaemia (lack of blood)
Hepatic failure (liver failure)
Platelet count decreased
Malignant neoplasm progression (cancer tumour came back)
Metastases to liver (cancer spreads to liver)
Pyrexia (fever)

50-59:

Febrile bone marrow aplasia (bone marrow greatly decreases or stops production of blood cells)
Herpes zoster
Infusion related reaction
Neuropathy peripheral (surface nerve damage)
Pruritus (severe itching of the skin)
Stomatitis (inflammation of mucous membrane of mouth)
Asthma
Cyanosis (lack of oxygen in body leads to blue appearance of skin ,mucous membrane nails)
Oedema peripheral (superficial swelling)
Pain in extremity

60+:

Mucosal inflammation (infection of mucous membrane)
Diarrhoea
Cardiac failure
Pneumonia
Pulmonary oedema (fluid accumulation in the lungs)
Dehydration (dryness resulting from the removal of water)
Disseminated intravascular coagulation (systemic activation of blood coagulation)
Hepatic cirrhosis (chronic liver disease characterized by replacement of liver tissue by fibrosis, scar tissue)
Radiation skin injury
Septic shock (shock due to blood infection)

What are the existing conditions these people have? *

Colon Cancer: 32 people, 45.71%
Oedema (fluid collection in tissue): 10 people, 14.29%
Insomnia (sleeplessness): 7 people, 10.00%
Hypopharyngeal Cancer: 7 people, 10.00%
Cancer Pain: 6 people, 8.57%
Cancer - Throat Or Larynx: 6 people, 8.57%

* Approximation only. Some reports may have incomplete information.

Do you take Aldactone and Erbitux?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously